Navigation Links
Neuralstem CEO To Present At Stem Cells & Regenerative Medicine Congress
Date:9/26/2013

ROCKVILLE, Md., Sept. 26, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO, Richard Garr, will present at the Stem Cells & Regenerative Medicine Congress, on Monday, September 30 at 12:00 PM at the Hyatt Regency in Cambridge, MA (http://www.terrapinn.com/2013/stem-cells-usa-regenerative-medicine/index.stm). Mr. Garr will give an overview of Neuralstem's ongoing trial testing NSI-566 stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), now in Phase II, as well as a clinical progress update.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

In a separate presentation, ALS patient, Ted Harada, who received transplants in both his lumbar and cervical spinal regions in Phase I of the Neuralstem trial, will talk about his experience as a patient on Monday, September 30, at 9:00 AM.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem's NSI-566 spinal cord-derived stem cell therapy is in an FDA-approved Phase II clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is conducting a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information 

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2012 and the Form 10-Q for the period ended June 30, 2013.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
7. Neuralstem Announces Proposed Public Offering
8. Neuralstem to Raise $7.0 Million in Registered Direct Offering
9. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
10. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
11. Neuralstem Secures $8 Million In Debt Financing From Hercules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Liver Cirrhosis Drugs Price Analysis and Strategies ... Cirrhosis market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Liver Cirrhosis ...
(Date:2/21/2017)... and Markets has announced the addition of the "Rosacea Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Rosacea ... market? What are the unit prices and annual treatment ...
(Date:2/21/2017)... Research and Markets has announced the addition of ... to their offering. ... latest research Anthrax Drugs Price Analysis and Strategies - 2016, provides drug ... research answers the following questions: What are the ... positioned in the Global Anthrax market? What are the ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies Inc., the world ... visit this week at HIMSS 2017 Conference & Exhibition. The event brings more ... will be featured in the conference’s Connected Health Experience section, an area specifically ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is ... of the company. The new location will triple the size of the previous location ... the town of Sunapee, NH. , “We are excited to expand our footprint ...
(Date:2/20/2017)... ... ... Johns Hopkins All Children's Hospital celebrated a major milestone with the topping ... the halfway point of construction and lifting of the final beam on the top ... center for innovation aimed at finding new discoveries and treatments for childhood diseases. The ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... company for eye care providers and health plan partners, announced during the 2017 ... the organization’s success enhancing care coordination for diabetic patients and integrating eye ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... The Citadel’s ... undergraduate nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged by ... operations of the nursing department in early 2016. After a nation-wide search, she was ...
Breaking Medicine News(10 mins):